Clinical trials are the most expensive and risky part of bringing a new drug to market, and the industry knows it. According to Swissinfo, ask a pharmaceutical company about the current approach and you're likely to hear "a chorus of complaints about a broken and dysfunctional system."
Artificial intelligence is increasingly seen as a way out of that dysfunction. Proponents say it holds "great promise for the entire drug development lifecycle," from finding the right patients to analyzing mountains of trial data faster than any human team could.
But enthusiasm is being tempered by a clear warning from experts: the technology is only as good as the people behind it. According to Forbes, any new AI tool should always be implemented with the end goal in mind — helping patients — not just streamlining processes or cutting costs.
That human-first framing matters because clinical trials are, at their core, about testing treatments on real people. Errors or blind spots baked into an AI system don't stay abstract — they can affect which patients are enrolled, which signals get flagged, and ultimately which drugs reach the public.
The consensus emerging from researchers and industry observers is not that AI should be kept out of clinical development, but that it needs careful governance, clear accountability, and human experts who understand both the science and the technology's limitations.
As AI tools spread through the pharmaceutical pipeline, getting that human oversight right could determine whether the technology accelerates medical breakthroughs — or quietly introduces new risks into an already high-stakes process.